Current Price and Market Context
As of 15 Sep 2026, Abbott India’s stock closed at ₹25,586.10, up from the previous close of ₹25,272.60. The intraday range spanned from ₹25,140.50 to ₹25,662.90, indicating moderate volatility within the day. The stock remains significantly below its 52-week high of ₹31,495.00, reflecting a correction phase, while it hovers just above its 52-week low of ₹25,140.50. This price action suggests a consolidation zone near the lower end of its annual range.
Technical Trend and Momentum Indicators
The overall technical trend has shifted from bearish to mildly bearish, signalling a tentative improvement in market sentiment but still lacking strong bullish conviction. The Moving Average Convergence Divergence (MACD) remains bearish on both weekly and monthly timeframes, indicating that the stock’s momentum is still under pressure from a medium to long-term perspective. This bearish MACD suggests that the downward momentum has not yet been decisively reversed.
Relative Strength Index (RSI) readings on weekly and monthly charts show no clear signal, hovering in neutral zones. This lack of extreme RSI readings implies that the stock is neither overbought nor oversold, which aligns with the observed consolidation phase. Bollinger Bands also maintain a bearish stance on weekly and monthly scales, reflecting persistent downward pressure and potential for continued volatility.
On the daily front, moving averages have turned mildly bullish, signalling short-term buying interest. This divergence between short-term and longer-term indicators highlights a potential early stage of recovery or a technical bounce rather than a confirmed trend reversal.
Additional Technical Signals
The Know Sure Thing (KST) indicator presents a mixed view: bullish on the weekly timeframe but bearish monthly, reinforcing the notion of short-term strength amid longer-term caution. Dow Theory assessments align with this, showing mildly bearish trends on both weekly and monthly charts, suggesting that the broader market structure has yet to confirm a sustained uptrend.
On-Balance Volume (OBV) readings add further nuance. The weekly OBV is mildly bearish, indicating that volume trends have not strongly supported price gains recently. However, the monthly OBV is bullish, hinting at accumulation over a longer horizon, which could provide a foundation for future price appreciation if confirmed by other indicators.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Relative Performance Against Sensex
Abbott India’s returns compared to the Sensex over various periods reveal a mixed performance. Over the past week, the stock declined by 1.86%, slightly outperforming the Sensex’s 2.27% fall. However, over the last month, Abbott India’s loss of 8.65% significantly exceeded the Sensex’s 4.32% decline, indicating sector-specific or company-specific pressures.
Year-to-date (YTD), the stock has fallen 11.98%, marginally better than the Sensex’s 12.25% drop, but over the last year, Abbott India’s 17.40% decline notably underperformed the Sensex’s 8.30% loss. This underperformance over the 12-month horizon suggests challenges in regaining investor confidence.
Longer-term returns paint a more positive picture. Over three years, Abbott India has delivered an 11.29% gain, closely tracking the Sensex’s 11.40%. Over five years, the stock’s 23.61% appreciation, while respectable, lags behind the Sensex’s 28.26%. Remarkably, over a decade, Abbott India has surged 450.53%, vastly outperforming the Sensex’s 159.68% gain, underscoring its strong fundamental growth and value creation over the long haul.
Mojo Score and Rating Update
MarketsMOJO has upgraded Abbott India’s Mojo Grade from Sell to Hold as of 7 Sep 2026, reflecting a cautious but improved outlook. The current Mojo Score stands at 50.0, indicating a neutral stance with neither strong buy nor sell signals. This upgrade aligns with the technical trend shift to mildly bearish and the mixed signals from momentum indicators, suggesting that investors should monitor developments closely before committing to a position.
Sector and Market Capitalisation Context
Operating within the Pharmaceuticals & Biotechnology sector, Abbott India is classified as a mid-cap stock. This positioning implies a balance between growth potential and risk, with the sector’s inherent volatility influenced by regulatory developments, innovation cycles, and global health trends. The mid-cap status also means liquidity and analyst coverage are moderate, which can contribute to price swings based on technical factors.
Why settle for Abbott India Ltd.? SwitchER evaluates this Pharmaceuticals & Biotechnology mid-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Investor Takeaway and Outlook
Abbott India’s technical landscape presents a cautious scenario. The shift from bearish to mildly bearish trend and the daily moving averages’ mild bullishness offer tentative signs of stabilisation. However, the persistent bearish MACD and Bollinger Bands on weekly and monthly charts, combined with mixed KST and Dow Theory signals, counsel prudence.
Investors should weigh the stock’s near-term consolidation against its long-term outperformance and sector fundamentals. The neutral RSI and mixed volume trends suggest that a decisive breakout or breakdown could be imminent, making it essential to monitor key support levels near ₹25,140 and resistance around ₹26,000 to ₹26,500.
Given the current Mojo Grade of Hold and the technical indicators, a wait-and-watch approach may be prudent for risk-averse investors, while more aggressive traders might consider tactical entries on confirmed short-term strength. The stock’s relative underperformance over the past year compared to the Sensex also highlights the need for selective exposure within the Pharmaceuticals & Biotechnology sector.
Conclusion
Abbott India Ltd. is navigating a complex technical environment characterised by mixed momentum signals and a recent upgrade in analyst sentiment. While short-term indicators hint at mild bullishness, longer-term trends remain cautious. The stock’s historical resilience and strong decade-long returns provide a solid foundation, but near-term volatility and sector dynamics warrant careful analysis. Investors should remain vigilant to technical developments and broader market cues before adjusting their positions in this mid-cap pharmaceutical stock.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
